Efficacy of colchicine in moderately symptomatic COVID-19 patients: a study protocol for a double-blind, randomized, placebo-controlled trial
Background: Inflammation is playing a major role in the pathophysiology of severe COVID-19 disease. The main causes of mortality are cytokine syndrome and immune thromboembolism. Colchicine is an anti-inflammatory drug but its action is mediated by completely different pathophysiologic routes than that of corticosteroids and non-steroidal anti-inflammatory agents. Colchicine inhibits neutrophil chemotaxis, inhibits inflammasome signaling and reduces interleukin-1β, reduces neutrophil-platelet interaction and aggregation. Colchicine is a readily available, cheap drug, has been used safely for many years. Specific targeted anti-inflammatory drugs like tocilizuma and anakinra are costly. A previous study suggested a significant clinical benefit from colchicine in patients hospitalized with COVID-19. But they did not compare with placebo. So, we have designed this study.
Methods: This is a prospective, double-blind, randomized, placebo-controlled clinical trial. The study will be conducted at Dhaka medical college hospital, Bangladesh. Real time-polymerase chain reaction (RT-PCR) positive COVID-19 patients with moderate symptoms will be included in this study. Participants will be randomized into two groups at 1:1 ratio. Patients of one group will be treated with standard treatment along with colchicine for 14 days. The patients in other group will be treated with standard treatment along with placebo for the same duration. The primary outcome of the study will be time to develop clinical deterioration, defined as the time from randomization to a deterioration of two points (from the status at randomization) on a seven-category ordinal scale.
Conclusions: Enrolment of participants has begun at the study site. A total of 300 participants will be enrolled.
Trial Registration: ClinicalTrials.gov identifier: NCT04527562.
World health organization. Coronavirus disease (COVID-19) Situation Report–132 Data as received by WHO from national authorities. Available at: https://www.who.int/docs/defaultsource/coronaviruse/situation-reports/20200531-covid-19-sitrep-132.pdf?sfvrsn=d9c2eaef_2.) Accessed on: 31 May 2020.
Saey TH. Repurposed drugs may help scientists fight the new coronavirus. Available at: https://www.sciencenews.org/article/coronavirus-covid19-repurposed-treatments-drugs. Accessed on: 10 March 2020.
World health organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. Available at: https://www.who.int/emergencies/ diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(COVID-2019)-and-the-virus-that-causes-it. Accessed on: 20 April 2020.
Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chinese Med J. 2020;133(9):1015-24.
Focos D, Anderso A, Tang J, Tuccori M. Convalescent plasma therapy for COVID 19. Preprints (www.preprints.org). 2020.
lauer SA, Grantz KH, Jones FK. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020;172(9): 577-82.
Liu Z, Chu R, Gong L, Su B, Wu J. The assessment of transmission efficiency and latent infection period in asymptomatic carriers of SARS-CoV-2 infection. Int J Infect Dis. 2020;99:325-327.
Antonio V, Francesco F, Chiara P, Giovanni G.Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia. Italian J Med. 2020;14(2).
Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and Multiorgan Response. Curr Probl Cardiol. 2020;45(8):100618.
Baraboutis IG, Gargalianos P, Aggelonidou E. Initial Real-Life Experience from a Designated COVID-19 Centre in Athens, Greece: a Proposed Therapeutic Algorithm. SN Compr Clin Med. 2020;2:689-93.
Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, Walzer T, François B, Sève P. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19(7):102567.
Zhang W, Zhao Y, Zhang F. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393.
Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020;39(7):2085-94.
Deftereos S, Giannopoulos G, Vrachatis DA, Siasos G, Giotaki SG, Cleman M, et al. Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks? Eur Heart J - Cardiovasc Pharmacother. 2020;6(4):255.
Deftereos SG, Giannopoulos G, Vrachatis DA. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. JAMA Netw Open. 2020;3(6):e2013136.
National Guidelines on Clinical Management of Coronavirus Disease 2019 (COVID-19).Version 7.0 28 May, 2020, DGHS, MOHFW, Government of the People's Republic of Bangladesh.
World health organization. Coronavirus disease (COVID-2019) R&D. Available at: https://www.who.int/blueprint/priority-diseases/ keyaction/novel-coronavirus/en/. Accessed on: 25 March 2020.
Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, et al. Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection. J Infect Dis. 2020;221(10):1688-98.
Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382:1787-99.
Sakpal TV. Sample Size Estimation in Clinical Trial. Perspect Clin Res. 2010;1(2):67-9.